Neuroendocrine Tumors
Who we are
A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
